Suzhou-based biomedical company Gracell Biotechnologies has raised $85 million in a Series B funding round led by Singapore’s state investment firm Temasek, per an announcement on Monday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
